Business Wire

PSE

26.11.2018 18:50:10 CET | Business Wire | Press release

Share
PSE awards €5000 Model-Based Innovation prizes

Process Systems Enterprise (PSE), the Advanced Process Modelling company, today announced the winners of the prestigious PSE Model-Based Innovation (MBI) Prize for 2018.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181126005616/en/

PSE, providers of the world-leading gPROMS® modelling platform used for digital design and operations throughout the process industries, awards an annual €3000 winner’s prize and two runners-up prizes of €1000 each for the most innovative use of advanced process modelling techniques in support of published research.

The winners are Johannes Schilling* and Andre Bardow of RWTH Aachen University, and Joachim Gross of Stuttgart University, Germany for their paper Integrated design of ORC process and working fluid using process flowsheeting software and PC-SAFT, published in Proceedings of the IV International Seminar on ORC Power Systems, ORC2017, Italy.

The judges summarised the research as “excellent work investigating the integration of Computer Aided Molecular Design (CAMD) with the gPROMS flowsheeting environment for the integrated design of process and working fluid. Several model libraries in gPROMS ProcessBuilder® were adapted to employ the Variable Molecular Structure Compound feature of the gSAFT® advanced thermodynamic package during process optimisation. The resulting mixed-integer non-linear (MINLP) optimisation simultaneously determined the optimal molecular structure for the working fluid and the corresponding optimal process design”.

Runners up were Seo-Young Park*, Shaun C. Galbraith, Huolong Liu, Bumjoon Cha, Zhuangrong Huang and Seongkyu Yoon of the Department of Chemical Engineering, University of Massachusetts, Lowell, MA; HaeWoo Lee of Daegu-Gyeongbuk Medical Innovation Foundation, Daegu, South Korea; and Thomas O'Connor and Sau Lee of the U.S. Food and Drug Administration, for their paper Prediction of critical quality attributes and optimization of continuous dry granulation process via flowsheet modeling and experimental validation , and Dhia Y. Aqar* of the University of Bradford, UK and Ministry of Oil, Basra, Iraq; and Nejat Rahmanian and Iqbal M. Mujtaba of the University of Bradford, UK for their paper Feasibility of novel integrated dividing-wall batch reactive distillation processes for the synthesis of methyl decanoate . Full details can be found on the PSE website .

The prize is judged by team of leading academics in the field of process systems engineering, Prof. Stratos Pistikopoulos (chair) of Texas A&M Energy Institute, Associate Prof. Michael Georgiadis of the Aristotle University of Thessaloniki, Greece and Prof. Eva Sorensen of University College London.

gPROMS is widely used throughout the chemicals, energy, petrochemical, food and pharmaceuticals sectors, including in some 200 academic organisations. Pieter Schmal, Head of PSE Academic, says “We work closely with academic communities around the world to foster innovation, through our academic programme, the MBI Prize, our Partnerships for Advanced Process Modelling and the PSE Academic Teaching Highway (PATH). We congratulate our winners on the quality of their work.”

For editors

Editors: www.psenterprise.com/news/pr181126

Contact:

Kate Burness +44-20-8563-0888 k.burness@psenterprise.com

Link:

ClickThru

Social Media:

https://www.facebook.com//Process-Systems-Enterprise-Limited-PSE-194030330653358/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 09:00:00 CEST | Press release

Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, tod

U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 09:00:00 CEST | Press release

Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly

SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 09:00:00 CEST | Press release

The Memorandum of Understanding (MoU) and additional contract signal a new phase of collaboration on market development in the Asia Pacific (APAC) region SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter

Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 07:00:00 CEST | Press release

Extending Link-16 interoperability without platform-level hardware integration Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participant

Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 07:00:00 CEST | Press release

H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye